ReviewJournal of clinical medicine2024
Gout and Hyperuricemia: A Narrative Review of Their Comorbidities and Clinical Implications.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Effect of Hyperuricemia on Cognitive Impairment: A Cohort Study and Systematic Review.Nutrients · 2026Pooled it
- Metformin repurposing in gout: enhancing febuxostat efficacy through anti-inflammatory and metabolic modulation: a randomized controlled double-blind study.Inflammopharmacology · 2026Trial
- ABCG2 transporter: Structural and functional associations with gout (Review).International journal of molecular medicine · 2026Review
- Gout and Risk of Ischemic Stroke in Patients With Atrial Fibrillation: A Nationwide Cohort Study.Stroke · 2026Observational
- Explainable Clinical Decision Support for Metabolic Index Prediction in Gout Patients Using GA-Optimized Ensemble Learning Models.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Bile Acid Metabolism in Gout Pathogenesis from Gut-Liver-Joint Crosstalk to Therapeutic Opportunities.Metabolites · 2026Review
- Development and validation of a risk models for gout in patients with diabetic kidney disease.BMC endocrine disorders · 2026Article
- Nonlinear Association of the Triglyceride-Glucose Index With Hyperuricemia Among Young Chinese Adults.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Intestinal Multi-Target Mechanisms of Natural Active Substances in Hyperuricemia Alleviation: Recent Progress.Nutrients · 2026Review
- Gout flare burden as a marker of chronic kidney disease risk.BMC nephrology · 2026Article
- Article
- The impact of meteorological conditions on the occurrence of low back pain in a retrospective registry based population study.Scientific reports · 2026Article
- Structure-Based Virtual Screening of Plant-Derived Flavonoids as Putative GLUT9 Binders with Antioxidant Properties.Molecules (Basel, Switzerland) · 2026Article
- The imbalance of Th17/Treg cells exists in asymptomatic hyperuricemia (the early stage of gout).Clinical rheumatology · 2026Article
- NMR-based metabolomics in a clinical cohort: deciphering the metabolic characteristics of gout with the dampness-heat syndrome and elucidate the efficacy of Simiao Pill.Chinese medicine · 2026Article
- Structural divergence of lentinula edodes polysaccharides is associated with distinct anti-hyperuricemia pathways.NPJ science of food · 2026Article
- Juanbi Lijieqing Decoction Inhibits TLR4/NF-κB Signaling Pathway by Promoting PPARγ Expression to Relieve Acute Gouty Arthritis.Combinatorial chemistry & high throughput screening · 2026Article
- Serum uric acid levels and cardiorenal complication prevalence in hypertensive patients before and after the COVID-19 pandemic: a retrospective cross-sectional study from a tertiary traditional Chinese medicine hospital.Frontiers in endocrinology · 2026Article
- Hyperuricemic persons use more analgesics than normouricemic-is asymptomatic hyperuricemia really asymptomatic?BMC medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gout is the most common form of inflammatory arthritis, caused by the deposition of monosodium urate crystals in the joints due to elevated serum uric acid levels. Its prevalence and associated healthcare burden have been rising in recent decades, a trend expected to continue. It is crucial to recognize that gout and hyperuricemia are not merely causes of painful joint flares, but systemic metabolic disorders linked to a broad spectrum of comorbidities such as cardiovascular diseases, chronic kidney disease, diabetes, insulin resistance, steatotic liver disease, osteoarthritis, and respiratory and eye diseases. Numerous risk factors for gout and hyperuricemia have been identified, with recent research uncovering further associations with other conditions. To optimize patient outcomes, gout and hyperuricemia must be addressed through a holistic approach that accounts for these risk factors while providing comprehensive management of related comorbidities affecting various organ systems. This review summarizes the current knowledge on the risk factors, comorbidities, and clinical implications of gout and hyperuricemia. Future research should focus on improving patient outcomes by tailoring treatments individually and addressing the underlying metabolic comorbidities of gout with multimodal treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.